OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
7062$840.0058

Fureasu Co Ltd

Healthcare Facilities & ServicesVerified

Fureasu's capital structure is highly leveraged, with a debt-to-equity ratio of 3.96, indicating significant reliance on long-term debt to fund operations. The company's liquidity position is constrained, as evidenced by negative free cash flow of ¥177.5 million and operating cash flow of ¥-319.2 million, despite holding ¥815 million in cash and equivalents. The current ratio of 1.63 suggests moderate short-term liquidity, but the negative net cash position after subtracting total debt raises concerns about near-term solvency. Profitability metrics are sharply negative, with a return on equity of -15.79% and return on assets of -2.81%, both well below the industry median for healthcare services. The company reported a net loss of ¥244.5 million and operating loss of ¥106.2 million, indicating a failure to generate sustainable earnings from core operations. Gross profit of ¥3.24 billion represents 42.8% of revenue, but this is insufficient to cover operating expenses, which is a red flag for operational efficiency. The company's revenue is concentrated in its core massage and visiting nursing services, with no disclosed geographic diversification. All operations are based in Japan, and the business model is heavily dependent on the domestic healthcare insurance system. There are no material international revenue streams or segment disclosures to suggest diversification. Growth trajectory is negative, with no disclosed revenue growth in the most recent fiscal year. The company's market capitalization of ¥2.19 billion is significantly lower than its enterprise value to revenue multiple of 0.99, suggesting a distressed valuation. Analysts have confirmed the reported revenue of ¥7.58 billion, but the negative EPS of ¥-103.65 indicates a lack of earnings momentum. Risk factors include high leverage, negative cash flow, and a lack of earnings. The company's liquidity risk is rated as medium, with a current ratio of 1.63, but the negative net cash position after debt is a key flag. Dilution risk is currently low, with no recent share issuance or ATM programs disclosed, but the company's capital structure may require further financing in the near term. Recent events include the publication of the 2023 annual report, which confirmed the company's operating and financial losses. No material regulatory changes or new business initiatives were disclosed in the latest filings. The company remains focused on its core massage and nursing services, with no indication of strategic pivot or expansion.

30-day price · 7062(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyFureasu Co Ltd
Ticker7062.T
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Fureasu Co Ltd operates primarily in the massage and home healthcare services sector, providing insurance-covered massage services and visiting nursing care, with additional revenue from corporate-partnered SPA services.

Classification. Fureasu is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a confidence level of 0.92 based on verified market data.

Fureasu's capital structure is highly leveraged, with a debt-to-equity ratio of 3.96, indicating significant reliance on long-term debt to fund operations. The company's liquidity position is constrained, as evidenced by negative free cash flow of ¥177.5 million and operating cash flow of ¥-319.2 million, despite holding ¥815 million in cash and equivalents. The current ratio of 1.63 suggests moderate short-term liquidity, but the negative net cash position after subtracting total debt raises concerns about near-term solvency. Profitability metrics are sharply negative, with a return on equity of -15.79% and return on assets of -2.81%, both well below the industry median for healthcare services. The company reported a net loss of ¥244.5 million and operating loss of ¥106.2 million, indicating a failure to generate sustainable earnings from core operations. Gross profit of ¥3.24 billion represents 42.8% of revenue, but this is insufficient to cover operating expenses, which is a red flag for operational efficiency. The company's revenue is concentrated in its core massage and visiting nursing services, with no disclosed geographic diversification. All operations are based in Japan, and the business model is heavily dependent on the domestic healthcare insurance system. There are no material international revenue streams or segment disclosures to suggest diversification. Growth trajectory is negative, with no disclosed revenue growth in the most recent fiscal year. The company's market capitalization of ¥2.19 billion is significantly lower than its enterprise value to revenue multiple of 0.99, suggesting a distressed valuation. Analysts have confirmed the reported revenue of ¥7.58 billion, but the negative EPS of ¥-103.65 indicates a lack of earnings momentum. Risk factors include high leverage, negative cash flow, and a lack of earnings. The company's liquidity risk is rated as medium, with a current ratio of 1.63, but the negative net cash position after debt is a key flag. Dilution risk is currently low, with no recent share issuance or ATM programs disclosed, but the company's capital structure may require further financing in the near term. Recent events include the publication of the 2023 annual report, which confirmed the company's operating and financial losses. No material regulatory changes or new business initiatives were disclosed in the latest filings. The company remains focused on its core massage and nursing services, with no indication of strategic pivot or expansion.
Key takeaways
  • Fureasu is operating at a loss with negative cash flow and high leverage, raising concerns about solvency.
  • The company's return on equity and assets are sharply negative, indicating poor capital efficiency.
  • Revenue is concentrated in Japan with no geographic or segment diversification.
  • The valuation is distressed, with a price-to-book of 1.42 and EV-to-revenue of 0.99.
  • Liquidity is constrained, with negative net cash after debt and no near-term dilution pressure.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyJPY
Revenue$7.58B
Gross profit$3.24B
Operating income-$106.2M
Net income-$244.5M
R&D
SG&A
D&A
SBC
Operating cash flow-$319.2M
CapEx-$147.9M
Free cash flow-$177.5M
Total assets$8.70B
Total liabilities$7.15B
Total equity$1.55B
Cash & equivalents$815.0M
Long-term debt$6.14B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price$840.00
Market cap$2.19B
Enterprise value$7.52B
P/E
Reported non-GAAP P/E
EV/Revenue1.0
EV/Op income
EV/OCF
P/B1.4
P/Tangible book1.4
Tangible book$1.55B
Net cash-$5.32B
Current ratio1.6
Debt/Equity4.0
ROA-2.8%
ROE-15.8%
Cash conversion1.3%
CapEx/Revenue-1.9%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 25 companies
Metric7062Activity
Op margin-1.4%18.2% medp25 18.2% · p75 24.6%bottom quartile
Net margin-3.2%14.7% medp25 11.7% · p75 28.1%bottom quartile
Gross margin42.7%19.7% medp25 19.7% · p75 39.8%top quartile
R&D / revenue24.3% medp25 6.6% · p75 24.3%
CapEx / revenue-1.9%4.9% medp25 4.2% · p75 6.3%bottom quartile
Debt / equity396.0%71.3% medp25 19.0% · p75 91.7%top quartile
Observations
IR observations
Last actual EPS-103.65 JPY
Last actual revenue7,582,580,000 JPY
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-04 21:57 UTC#45b5d352
Market quoteclose JPY 840.00 · shares 0.00B diluted
no public URL
2026-05-04 21:57 UTC#0db82869
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 21:59 UTCJob: 77a5a7cc